Sleep disturbances are associated with future risk of Alzheimer disease. Disrupted sleep increases soluble amyloid b, suggesting a mechanism for sleep disturbances to increase Alzheimer disease risk. We tested this response in humans using indwelling lumbar catheters to serially sample cerebrospinal fluid while participants were sleep-deprived, treated with sodium oxybate, or allowed to sleep normally. All participants were infused with 13 C 6 -leucine to measure amyloid b kinetics. We found that sleep deprivation increased overnight amyloid b38, amyloid b40, and amyloid b42 levels by 25 to 30% via increased overnight amyloid b production relative to sleeping controls. These findings suggest that disrupted sleep increases Alzheimer disease risk via increased amyloid b production. ANN NEUROL 2018;83:197-204 A lzheimer disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment and neuropathologic extracellular plaques of amyloid b (Ab) and intracellular inclusions of tau. Sleep disturbances are associated with future risk of AD.
C 6 -leucine to measure amyloid b kinetics. We found that sleep deprivation increased overnight amyloid b38, amyloid b40, and amyloid b42 levels by 25 to 30% via increased overnight amyloid b production relative to sleeping controls. These findings suggest that disrupted sleep increases Alzheimer disease risk via increased amyloid b production. ANN NEUROL 2018; 83:197-204 A lzheimer disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment and neuropathologic extracellular plaques of amyloid b (Ab) and intracellular inclusions of tau. Sleep disturbances are associated with future risk of AD. [1] [2] [3] For example, women with sleep efficiency <70% are 1.61 times more likely to develop cognitive impairment than women with sleep efficiency 70% or greater. 1 Recent evidence suggests increased risk of AD from sleep disturbances may be due, at least in part, to an Ab mechanism. Diurnal oscillation of interstitial fluid (ISF) and cerebrospinal fluid (CSF) Ab concentrations in both mice and humans has been replicated in multiple studies using different assays. [4] [5] [6] [7] Ab aggregation as insoluble plaque is concentration-dependent and is hypothesized to be a key early step in AD pathogenesis. Sleep disruption in mice 4 and humans 8, 9 increases soluble Ab concentrations and, potentially, plaque deposition. Although these findings suggest sleep as a potential novel modulator of AD pathology, we do not know whether sleep alters Ab production and/or clearance, leaving a critical gap in our ability to pursue sleep modulation as a preventive strategy for AD. In this pilot study, we collected serial CSF from sleep-deprived, sleep-induced, and control participants who were infused with 13 C 6 -leucine to measure Ab stable isotope labeling kinetics (SILK).
Subjects and Methods

Participants and Sleep Interventions
Eight participants aged 30 to 60 years were recruited from both longitudinal studies at the Knight Alzheimer Disease Research Center and a research volunteer registry at Washington University (Volunteers for Health). Three participants were male. All participants were cognitively normal (Clinical Dementia Rating score of 0 or Mini-Mental Status Examination 27). 10, 11 Participant characteristics are shown in Table 1 . The study was conducted at the Washington University School of Medicine in St Louis, Missouri. The study protocol was approved by the Washington University Institutional Review Board and the General Clinical Research Center Advisory Committee. The Clinical Trials number was NCT02063217. All participants completed written informed consent and were compensated for their participation in the study. Participants were initially randomized to 1 of 3 groups: (1) behavioral sleep deprivation for 36 hours, (2) sleep induced with sodium oxybate, and (3) normal sleep (control). Sodium oxybate was selected for sleep induction because it enhances slow wave sleep (SWS). 12 Each participant was invited to repeat the study and undergo randomization to a different group. Four participants repeated the study once, and 4 participants completed all 3 groups. All participants were in good general health, had no clinical sleep or neurological diseases, and had no contraindication to a lumbar catheter. All participants were screened to exclude sleep-disordered breathing with a home sleep apnea test (Apnealink; ResMed, San Diego, CA). Polysomnography was performed as previously reported 5 throughout each participant's admission to the Clinical Research Unit. After an acclimation night, an intrathecal lumbar catheter was placed and collection of samples were started in all participants at 07:00. All participants were kept awake from the time of lumbar catheter placement (07:00) until the start of the intervention (21:00). At 21:00, control participants were permitted to sleep and participants in the sleepinduced group received their first dose of sodium oxybate. A second dose of sodium oxybate was administered at 01:00. Sodium oxybate doses ranged from 3.25 to 3.75g at both 21:00 and 01:00 (total dose 5 6.5-7.5g/night) and were adjusted for each participant for a range of 45 to 55mg/kg. Participants in the sleep-deprived group were kept awake by nursing staff and did not receive stimulants. The lumbar catheter was removed on day 2 at 19:00, and participants lay flat for 12 hours. Participants had meals served at 09:00, 13:00, and 18:00. Headaches were the most common adverse event, and 2 participants required blood patches for spinal headaches (see Table 1 ).
Sample Collection and Ab SILK Analysis
Six milliliters of CSF was obtained every 2 hours for 36 hours. All samples were processed and measured as previously described. 13 The procedure for stable isotope amino acid tracer administration, sample collection, and Ab SILK tracer protocol using a 9-hour infusion of [U-
13
C 6 ]leucine was performed as previously reported. 13 Ab SILK modeling was based on previously published models [13] [14] [15] with modifications necessitated by the reduced post-tracer sampling time compared to previous studies (22 vs 36 hours). The model consisted of a plasma leucine precursor pool that generated labeled Ab38, Ab40, and Ab42 peptides. Each arm of the model consisted of a time delay process and a single compartment process; the length of the time delay and the single compartment fractional turnover rate (FTR) was independently adjustable for each peptide. The FTR represents the sum of irreversible losses of brain peptides to all processes (eg, recovery in CSF, clearance through the blood-brain barrier, and in situ proteolysis, uptake, or deposition). The production rate of each peptide was determined as the flux rate through the terminal CSF sampling site of the model. Compartmental modeling was performed using SAAM II (v2.3.1; Epsilon Group, Charlottesville, VA). None of our participants had evidence of brain Ab deposition based on Ab42:Ab40 > 0.12; therefore, exchange of Ab42 with an "insoluble" compartment was not included. 13 
Statistics
Statistical analyses were performed using SPSS version 23 (IBM, Armonk, NY). All serial CSF Ab data were analyzed with general linear mixed models to account for the dependencies among the longitudinal measurements. 16 Intervention group and time of day were treated as fixed effects. Random intercepts and slopes for time were used to accommodate individual variation. The Akaike Information Criterion was used to compare covariance structures, and compound symmetry was selected as the best fit. Statistical significance was set at p < 0.05. Bonferroni correction was used when making comparison between the 3 intervention groups (0.05/3). The normality assumption was verified through residual plots. Differences in participant characteristics were also assessed with mixed models, as with the Ab models, but without a time factor.
Results
Ab concentrations were normalized to a baseline for each subject (average of hours 07:00-19:00) before each group's intervention. Mean overnight CSF Ab38, Ab40, and Ab42 concentrations increased 30% above baseline levels in sleep-deprived participants compared to the control and drug groups (Fig 1A-C , Table 2 ). There were no statistically significant differences between the control and drug groups. Figure 2 shows the change from baseline of Ab40 for each participant. Ab38 and Ab42 showed similar within-subject changes from baseline (data not shown). The time courses curves for 13 C 6 -leucine isotopic enrichment overlapped for Ab38, Ab40, and Ab42 (see Fig 1) ; the FTR of Ab peptides is extremely sensitive to the shape of these curves.
14 Ratios of labeled Ab38/40 and Ab42/40 were flat across the sampling period for all groups, showing that the peptides had equivalent FTRs. Formal modeling analysis revealed that the FTRs and delay times were not significantly different between groups (see Table 2 ), which strongly suggests a lack of sleep pattern on the overall clearance processes of brain peptides. Because production rate is directly proportional to concentration in the model, 14 overnight Ab production rate in the sleep-deprived group was increased 30%.
Discussion
Diurnal oscillation of Ab is hypothesized to result from (1) changes in Ab production by neuronal activity 17, 18 and (2) changes in Ab clearance via ISF bulk flow to cervical lymphatics and CSF during sleep (ie, "glymphatic " drainage). 19 During wakefulness, Ab concentration increases due to increased neuronal activity (production) and decreased ISF flow (clearance). Conversely, neuronal activity decreases and ISF flow increases during sleep, together accounting for a decrease in Ab concentration. As predicted and consistent with prior work, 8, 9 disrupted sleep resulted in higher overnight CSF Ab levels in our study. The effect of disrupted sleep on overnight CSF Ab levels in individual participants was variable, however (see Fig 2) . We hypothesize that this variability was due to factors not identifiable in our pilot study (age, gender, race, Apoe genotype). The absence of group differences from the Ab SILK puts constraints on the possible mechanisms that could account for the altered concentration time courses. We have previously shown that the shape of the kinetic curve is most sensitive to changes in clearance rates and is entirely unaffected by changes in production rate. 14 We performed sensitivity analyses using example data from 1 participant and held all model parameters constant except for either production rate or FTR. When the production rate was 1% or 199% of nominal, the SILK curves were identical (Fig 3A) . However, changes in FTR as small as 5% resulted in a noticeable change in peak shape and a small shift in peak time; 20% changes in FTR led to large changes in peak shape and peak time with separation of the labeling curves (see Fig 3B, C) .
Increased amyloid precursor protein (APP) production or increased cleavage of APP by b-secretase would increase the concentrations of all Ab isoforms without altering the shapes of the SILK curves. In PSEN1 mutation carriers without amyloid deposition, for example, increased Ab production does not alter the shape of 13 C 6 -leucine labeling curves. 14, 15 Furthermore, soluble CSF APP metabolites fluctuate with a diurnal pattern, 20 providing additional support that APP production is altered by sleep-wake activity. Sleep also did not alter labeled Ab38/Ab40 and Ab42/Ab40 ratios, suggesting sleep does not affect Ç-secretase activity.
A change in overall clearance will affect the FTR of brain Ab peptides, which is the sum of losses to CSF and all other fates. For decreased glymphatic clearance during sleep deprivation to increase soluble CSF Ab, a decrease in irreversible losses (eg, to the bloodstream or lymphatics) due to prolonged overnight waking would have to be perfectly matched by an increase in Ab clearance to CSF. This is plausible but unlikely and not identifiable from the current data. The SILK kinetics results unequivocally show that glymphatic clearance alone, without compensation from other clearance mechanisms, would be ineffective in protecting the brain from AD because overall clearance rates do not change. Glymphatic clearance may potentially contribute to the protective effects of sleep against AD, but changes in production rate seem to be the necessary and critical factor.
This pilot study provides the first evidence in humans that Ab production is the mechanism for sleepmediated changes in Ab concentration. We did not find that increased SWS from sodium oxybate decreased Ab compared to controls, possibly because time in SWS was not significantly different between the sleep-induced and control groups. Also, our study excluded participants with sleep disturbances; further decreasing Ab with sleep enhancement may not be feasible in normal subjects. Given that there are many approved therapies targeting sleep, the effect of sleep-inducing drugs on CSF Ab should be tested in individuals with sleep disruption and promising candidates investigated in AD prevention trials.
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